SDSarah Djabarouti

Sarah Djabarouti

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sarah Djabarouti has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Preliminary pharmacokinetic investigation of two discoidin domain receptor 2 inhibitors in murine plasma and brain using liquid chromatography–tandem mass spectrometry analysis

    by Paul Gueroue, Audrey Burban, Ahmad Sharanek, Guillaume Bougueon, Stéphane Bouchet, Dominique Ducint, Mathieu Molimard, Sarah Djabarouti, Joris Guyon

    Owing to its involvement in extracellular matrix–glial cell interactions, discoidin domain receptor 2 (DDR2) has emerged as a promising pharmacological target in various human diseases, including cancers and neurodegenerative disorders. Two allosteric inhibitors, WRG-28 and DDR2-IN-1, selectively target DDR2. Their therapeutic efficacy is likely to depend on blood–brain barrier (BBB) penetration; however, a lack of analytical methods has so far left their pharmacokinetic properties and BBB permeability profiles largely unexplored. In this study, a liquid chromatography–tandem mass spectrometry method was developed and validated for the simultaneous quantification of WRG-28 and DDR2-IN-1 in plasma and brain tissue. The extraction procedure was simple and based on protein precipitation followed by lipid removal. This analytical method met the acceptance criteria of the European Medicines Agency guidelines. The calibration range was linear from 1 to 1000 ng/mL for both compounds. In addition, five prediction software tools were used to estimate pharmacokinetic parameters relevant to the BBB penetration of the two compounds. Finally, the method was applied in preclinical pharmacokinetic studies using elacridar, an efflux transporter inhibitor.

  • Open Access

    Development and Validation of a LC‐MS/MS Method for Ripretinib and Its Metabolite: Example of a Journey From Laboratory Bench to Routine Application With a Greenness Assessment

    by Cedric Rakotovao, Ahmad Sharanek, Audrey Burban, Paul Gueroue, Stéphane Bouchet, Guillaume Bouguéon, Dominique Ducint, Mathieu Molimard, Antoine Italiano, Sarah Djabarouti, et al.

    Therapeutic drug monitoring of protein kinase inhibitors is widely practiced worldwide. Based on the example of ripretinib dosage requested by a clinician, we detailed the process of method development, using a literature‐based approach while ensuring the sustainability of the method to be as environmentally friendly as possible. Therefore, a UPLC‐MS/MS method for ripretinib and its active metabolite was optimized and validated using the corresponding stable isotopic internal standards in human plasma. The procedure employed a mobile phase mixture of water with 1% acetic acid and 0.1% formic acid, and acetonitrile. Positive electrospray ionization was performed, coupling with multiple reaction monitoring of m/z 510.4 → 417.4 and 510.4 → 389.4 for ripretinib, and 496.3 → 403.3 and 496.3 → 375.3 for N‐desmethyl‐ripretinib. The method was successfully validated according to the current version of the ICH Guideline provided by the EMA. The greenness assessment score of this procedure was better than previously published approaches using the AGREE metric. The validated UPLC‐MS/MS method successfully monitored ripretinib and its metabolite concentrations in clinical and preclinical models.

  • Open Access

    Development and validation of a LC-MS/MS method for ripretinib and its metabolite: example of a journey from laboratory bench to routine application with a greenness assessment

    by Cedric Rakotovao, Ahmad Sharanek, Audrey Burban, Paul Gueroue, Stéphane Bouchet, Guillaume Bouguéon, Dominique Ducint, Mathieu Molimard, Antoine Italiano, Sarah Djabarouti, et al.

    Therapeutic drug monitoring of protein kinase inhibitors is a widely practiced worldwide. Based on the example of ripretinib dosage requested by a clinician, we detailed the process of method development, using a literature-based approach while ensuring the sustainability of the method to be as environmentally friendly as possible. Therefore, an UPLC-MS/MS method for ripretinib and its active metabolite was optimized and validated using the corresponding stable isotopic internal standards in human plasma. The procedure has employed mobile phase mixture of water with 1% acetic acid and 0.1% formic acid, and acetonitrile. Positive electrospray ionization was performed coupling with multiple reaction monitoring of m/z 510.4→417.4 and 510.4→389.4 for ripretinib, and 496.3→403.3 and 496.3→375.3 for N-desmethyl-ripretinib. The method was successfully validated according the current version of ICH Guideline provided by the EMA. The greenness assessment score of this procedure was evaluated and compared with previously published approaches using the AGREE metric. The validated UPLC-MS/MS method successfully monitored ripretinib and its metabolite concentrations in clinical and pre-clinical models.